GO
| HSI1 | 25,852.92 | -156.48 | 257.82B |
| HSCEI1 | 8,574.26 | -77.89 | 78.01B |
| Back Zoom + Zoom - Block Traded | |
|
ALPHAMAB-B: NDA for KN026 Neoadjuvant Therapy for HER2-positive Breast Cancer Accepted by CN NMPA
2026-08-04 18:07:53 ALPHAMAB-B (09966.HK) announced that the new drug application (NDA) for Anbenitamab (trade name: 恩尼妥, R&D code: KN026), co-developed with JMT-Bio, a subsidiary of CSPC PHARMA (01093.HK), in combination with the docetaxel (albumin-bound) for injection (HB1801), as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2)-positive early or locally advanced breast cancer, has been accepted by the National Medical Products Administration of China (NMPA) and included in the priority review and approval procedure. ~ AASTOCKS Financial News Website: www.aastocks.com | |